# Anixa Biosciences Inc: overview ANIX · Nasdaq · CIK 715446 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Oct 31 Pages: [Overview](/companies/anix.md) · [Financials](/companies/anix/financials.md) · [Filings](/companies/anix/filings.md) · [Insiders](/companies/anix/insiders.md) Latest reported revenue: [$0](/filings/0001493152-25-001787.md) for Q4 FY2023, three months to 2023-10-31, from the 10-K filed Jan 10, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-25-001787). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(0.10)](/filings/0001493152-26-009370.md) | [(0.09)](/filings/0001493152-26-028105.md) | [(0.07)](/filings/0001493152-26-041963.md) | not reported | [(0.08)](/filings/0001493152-26-009370.md) | [(0.07)](/filings/0001493152-26-028105.md) | [(0.08)](/filings/0001493152-26-041963.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-10-31) | FY2022 (2022-10-31) | FY2023 (2023-10-31) | FY2024 (2024-10-31) | FY2025 (2025-10-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [512](/filings/0001493152-23-000346.md) | not reported | [210](/filings/0001493152-25-001787.md) | [210](/filings/0001493152-25-001787.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(2565.6%)](/filings/0001493152-23-000346.md) | not reported | [(5243.3%)](/filings/0001493152-25-001787.md) | [(6586.2%)](/filings/0001493152-26-001845.md) | not reported | | Net margin | % | [(2530.1%)](/filings/0001493152-23-000346.md) | not reported | [(4671.9%)](/filings/0001493152-25-001787.md) | [(5978.1%)](/filings/0001493152-26-001845.md) | not reported | | Diluted EPS | $ per share | [(0.45)](/filings/0001493152-22-000302.md) | [0.45](/filings/0001493152-24-002453.md) | [(0.32)](/filings/0001493152-25-001787.md) | [(0.39)](/filings/0001493152-26-001845.md) | [(0.34)](/filings/0001493152-26-001845.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/anix/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-23 | [Titterton Lewis H jr](/insiders/1499254.md) | Director | Purchase (P) | 8,000 | $2.98 | $23.8k | [Form 4](/filings/0001493152-26-048520.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.7m | 1,329,852 | | Added +14,870 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $1.6m | 585,430 | | Added +33,793 | | [Laird Norton Wetherby Trust Company, LLC](/funds/723204.md) | 2026-06-30 | $1.6m | 578,727 | | Added +12,400 | | [D.A. DAVIDSON & CO.](/funds/1080107.md) | 2026-06-30 | $1.5m | 539,272 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.0m | 359,194 | | Reduced −5,537 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $919.3k | 328,332 | | Added +155,153 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $559.3k | 199,755 | | Added +29,652 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $538.6k | 192,356 | | Added +1,282 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $445.3k | 159,040 | | Unchanged | | [LPL Financial LLC](/funds/1403438.md) | 2026-06-30 | $312.3k | 111,535 | | Added +30,559 | ## Recent filings [All 802 filings](/companies/anix/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-09 | 16:15 ET | [10-Q](/filings/0001493152-26-041963.md) | Quarterly report, period 2026-07-31 | 0001493152-26-041963 | | 2026-06-10 | 16:15 ET | [10-Q](/filings/0001493152-26-028105.md) | Quarterly report, period 2026-04-30 | 0001493152-26-028105 | | 2026-03-11 | 17:03 ET | [8-K](/filings/0001493152-26-009699.md) | 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-009699 | | 2026-03-09 | 16:16 ET | [10-Q](/filings/0001493152-26-009370.md) | Quarterly report, period 2026-01-31 | 0001493152-26-009370 | | 2026-02-09 | 08:02 ET | [8-K](/filings/0001493152-26-005702.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-005702 | | 2026-01-28 | 16:16 ET | [DEF 14A](/filings/0001493152-26-004035.md) | Proxy statement, period 2026-01-28 | 0001493152-26-004035 | | 2026-01-12 | 16:01 ET | [10-K](/filings/0001493152-26-001845.md) | Annual report, period 2025-10-31 | 0001493152-26-001845 | | 2026-01-06 | 19:48 ET | [SCHEDULE 13D/A](/filings/0001493152-26-000691.md) | Ownership report, active investor, amended | 0001493152-26-000691 | | 2025-12-12 | 18:34 ET | [8-K](/filings/0001493152-25-027321.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-25-027321 | | 2025-09-10 | 16:30 ET | [10-Q](/filings/0001493152-25-013000.md) | Quarterly report, period 2025-07-31 | 0001493152-25-013000 | ## Latest annual report [Form 10-K for the fiscal year ended Oct 31, 2025](/filings/0001493152-26-001845.md), filed Jan 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 715446 - Tickers: ANIX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:16 ET. No prices; not investment advice.